@kenlipartito @__philipn__ @j_g_allen The statement made was correct.
The standard set prior to approval was 50% reduction in symptomatic disease. They don't meet that any more, particularly the two dose unboosted series (boosted may, but only for a relatively short time).
@肯利帕蒂托(kenlipartito)菲利浦(philipn)艾伦(kenlipartito)所作的声明是正确的。
批准前设定的标准是症状性疾病减少50%。他们不再满足这一要求，尤其是两剂非胶囊系列（5月增加，但仅在相对较短的时间内）。